Immunology and inflammation

News

Sanofi's R&D platform building continues with $6bn-plus IGM ...

Sanofi has agreed another deal to flesh out its R&D pipeline, paying IGM Biosciences $150 million upfront to gain access to its engineered IgM antibody technology across six targets in

News

Etrasimod data suggests Pfizer's $6.7bn gamble on Arena will...

It's only been two weeks since Pfizer closed its $6.7 billion takeover of Arena Pharmaceuticals, and it already has the positive data it was hoping for with etrasimod, the main asset in the

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer's spesolimab data raises hope for serious skin di...

Fresh from being awarded a fast-track review from the FDA, Boehringer Ingelheim's spesolimab has shown encouraging efficacy in a phase 2 trial in generalised pustular psoriasis (GPP), a rar

News

FDA knocks back Takeda's blockbuster hope TAK-721

Japanese drugmaker Takeda has suffered a blow to its late-stage pipeline, after the FDA rejected its marketing application for TAK-721, a drug candidate that is trying to be the first appro

News

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for chronic spontaneous urticaria (CSU) for many years, but with biosimilars looming the company has been looking

News

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etras

Sanofi's R&D platform building continues with $6bn-plus IGM ...

Etrasimod data suggests Pfizer's $6.7bn gamble on Arena will...

Boehringer's spesolimab data raises hope for serious skin di...

FDA knocks back Takeda's blockbuster hope TAK-721

Blow for Novartis as ligelizumab can't top Xolair in phase 3

Flush with COVID cash, Pfizer tables $6.7bn bid for Arena

FDA cites 'significant concerns' with ADC lymphoma trial

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks